Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Non-Current Assets (2019 - 2025)

Historic Non-Current Assets for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to $58.6 million.

  • C4 Therapeutics' Non-Current Assets fell 4299.05% to $58.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $309.2 million, marking a year-over-year decrease of 2840.24%. This contributed to the annual value of $91.8 million for FY2024, which is 1275.58% down from last year.
  • C4 Therapeutics' Non-Current Assets amounted to $58.6 million in Q3 2025, which was down 4299.05% from $71.8 million recorded in Q2 2025.
  • C4 Therapeutics' 5-year Non-Current Assets high stood at $212.5 million for Q1 2022, and its period low was $50.9 million during Q2 2021.
  • In the last 5 years, C4 Therapeutics' Non-Current Assets had a median value of $105.0 million in 2024 and averaged $111.3 million.
  • As far as peak fluctuations go, C4 Therapeutics' Non-Current Assets surged by 84660.46% in 2021, and later tumbled by 4467.65% in 2023.
  • Over the past 5 years, C4 Therapeutics' Non-Current Assets (Quarter) stood at $181.1 million in 2021, then fell by 20.87% to $143.3 million in 2022, then dropped by 26.54% to $105.3 million in 2023, then dropped by 12.76% to $91.8 million in 2024, then plummeted by 36.16% to $58.6 million in 2025.
  • Its last three reported values are $58.6 million in Q3 2025, $71.8 million for Q2 2025, and $87.0 million during Q1 2025.